Abstract
Most cancer chemotherapy protocols in current use have been established empirically, and combination therapies have generally been designed based on single-agent activity and nonoverlapping toxicities. However, advances in our understanding of the molecular pathophysiology of human cancers indicate
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have